GenSight Biologics receives Orphan Drug Designation and Advanced Therapy Medicinal Product classification in Europe for GS030 in Retinitis Pigmentosa

GenSight Biologics confirms the success of its IPO by exercising 88.9% of the over-allotment option

GenSight Biologics announces the implementation of a liquidity contract with Oddo & Cie

GenSight Biologics announces successful IPO on Euronext Paris

GenSight Biologics launches its Initial Public Offering on the regulated market of Euronext in Paris

GenSight Biologics announces additional promising results of its Phase I/II study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)

GenSight Biologics announces the registration of its document de base in relation to its planned IPO on Euronext’s regulated market in Paris

GenSight Biologics Enrolls First Patient in Pivotal Phase III Program of GS010 in Leber’s Hereditary Optic Neuropathy

GenSight Biologics Receives IND Acceptance from FDA to Enter Phase III with GS010

GenSight Biologics Closes $36 Million Series B Preferred Stock Financing